Anebulo Pharmaceuticals Inc. Completes Oversubscribed Share Repurchase Tender Offer

Anebulo Pharmaceuticals Inc. (NASDAQ: ANEB) announced the successful conclusion of a share repurchase tender offer that attracted significant investor interest. The company received a high volume of bids, resulting in an oversubscribed transaction that was fully executed.

Key Details of the Repurchase

  • Offer Size: The tender offer involved a substantial portion of the company’s outstanding shares, reflecting a strong commitment to shareholder value.
  • Subscription Level: Investor demand exceeded the offer’s available shares, indicating robust confidence in the company’s prospects.
  • Execution: All accepted bids were processed, and the shares were subsequently retired, reducing the overall share count.

Market Reaction

  • After‑Hours Trading: Following the announcement, ANEB shares advanced 8.41% to $1.16 in after‑hours trading on January 23, 2026, before the formal completion of the tender offer.
  • Broader Biotech Context: The positive movement coincided with gains across the biotech sector, where several peers, such as Sarepta Therapeutics and Fractyl Health, experienced significant after‑hours momentum.
  • Investor Sentiment: The oversubscription is interpreted as a signal of investor confidence in Anebulo’s long‑term strategy, particularly its focus on disruptive treatments for substance use disorders.

Company Position

Anebulo remains a clinical‑stage biotechnology firm headquartered in Lakeway, United States, specializing in novel therapies for cannabinoid overdose and broader addiction landscapes. The company’s market capitalization stands at approximately $44.4 million USD, with a recent closing price of $1.08 on January 25, 2026. Despite a negative price‑earnings ratio of –4.83, the share repurchase underscores management’s belief that the stock is undervalued relative to its future potential.

This article summarizes publicly available information regarding Anebulo Pharmaceuticals Inc.’s share repurchase activity and related market performance.